Celyad SA rises as FDA permits clinical testing of cancer therapy
02/07/2019 18:39
** U.S.-listed shares of Belgium-based drug developer
CYAD.O up 12.3% at $13.5
** U.S. FDA accepts co's new manufacturing process and
application to begin clinical studies for its experimental
cancer therapy CYAD-02 urn:newsml:reuters.com:*:nGNX7GmMVQ
** Says early-stage trial for CYAD-02 to start in early 2020
** SunTrust Robinson Humphrey says the trial is beginning
earlier than expected as according to co's previous guidance the
application was to be filed by first half of 2020
** Up to Monday's close, U.S. listed shares of CYAD had
slumped ~34% YTD
(Reporting by Manojna Maddipatla in Bengaluru)
((Reuters Messaging:
manojna.kalyani.thomsonreuters.com@reuters.net))